Aurora Cannabis Inc. Common Shares - $ACB STOCK NEWS

Aurora Cannabis Inc. (ACB) and MedReleaf Australia have expanded their product offerings in Australia by introducing a new line of premium dried cannabis flower products. These products, including proprietary cultivars like Black Jelly, Chemango Kush, and Moon Berry, aim to provide patients with more choice and high-quality medical cannabis solutions. The expansion also includes the relaunch of the Vespera cultivar under the Aurora brand. The products are distributed by MedReleaf Australia, positioning itself as a leading distributor in the Australian market.

Aurora Cannabis Inc. applauds Germany's cannabis legalization, expecting it to boost the medical cannabis market expansion in the country. The reclassification of cannabis as a non-narcotic will enhance patient access and education, benefiting Aurora's position as a leading provider of medical cannabis in Germany.

Aurora Cannabis Inc. achieves Good Manufacturing Practice certification from Australia's Therapeutic Goods Administration for its Canadian production facilities, enhancing its position in the Australian medical cannabis market.

Aurora Cannabis Inc. and MedReleaf Australia have launched medical cannabis pastilles in Australia, offering greater choice for patients. The pastilles come in three formats, including THC, CBD, and balanced options. MedReleaf Australia aims to provide consistent and high-quality products to Australian patients, with plans for future innovations under the Aurora and IndiMed brands.

Aurora Cannabis Inc. announces the repayment of $7.2 million in convertible senior notes, marking a significant milestone in reducing debt. The total cash cost, including accrued interest, amounts to $7.4 million. The remaining debt of $47.9 million is related to Bevo Farms Ltd. CEO Miguel Martin highlights the company's focus on balance sheet strength and financial discipline to achieve positive free cash flow this year.

Aurora Cannabis Inc. partners with Script Assist to empower UK patients with high-quality medical cannabis products and guidance. The partnership aims to enhance the UK medical cannabis landscape by providing access to premium products and valuable information through an innovative technology platform.

Aurora Cannabis Inc. appoints Simona King, a former Bristol Myers-Squibb executive, as the new Chief Financial Officer. The company also completes a share consolidation on a 10 to 1 basis, with trading under the symbol 'ACB' on NASDAQ and TSX.

Aurora Cannabis Inc. re-affirms its commitment to achieving positive free cash flow in 2024 and delivers its fifth consecutive quarter of positive adjusted EBITDA. The company has become the largest global medical cannabis company in nationally legal markets following the acquisition of MedReleaf Australia, and has experienced strong YoY growth in high-margin international net cannabis revenue. They reported a cash position of over $200 million and expect to fully repay remaining convertible debt of $7.3 million in February. The company's fiscal 2024 is on track to be their strongest year yet, with 41% YoY growth in international medical net revenue. They also anticipate achieving positive adjusted EBITDA on an annualized basis for the first time in fiscal 2024. The acquisition of MedReleaf Australia is expected to be immediately accretive to Adjusted EBITDA, while accelerating their path to generate positive free cash flow this calendar year. Aurora expects steady revenue from Canadian medical and consumer segments, modest growth in Europe and Australia, and seasonally higher revenues and gross profit from plant propagation in fiscal Q4 2024. They have repurchased approximately $23.1 million in principal amount of convertible debentures and expect to be debt-free by the end of February 2024.

Aurora Cannabis Inc. has acquired the remaining 90% equity interest of MedReleaf Australia for AUD$50 million, making it the largest global medical cannabis company operating in nationally legal markets. The transaction is expected to be immediately accretive to Adjusted EBITDA and accelerate the Company's plan for Positive Free Cash Flow generation in 2024. The Australian medical cannabis market is rapidly growing and is estimated to be worth approximately AUD$400 million, with MedReleaf Australia holding the #2 position in the market. The acquisition is a strategic milestone for Aurora, strengthening its presence in Australia and supporting its path to profitability.